Kelvin Bench

A $18,000 benchtop robot that runs any wet-lab protocol written in plain English.

Kelvin Bench is a benchtop liquid-handling and imaging robot sold outright to small labs: a two-person biotech, a university group, a contract formulation shop.

Hardware
Small business
$1-10B market
Platform others build on
Global from day one

3/5

venture judge

similar startups, last 2 years (1 all-time)

97%

of 4 nearest real companies still alive

yes

1 matching federal grants and programs

Direction supported by government programs and grants

Scorecard

One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.

Idea Score, 0-100 · raw 45.7 x 1.64

Warm

competition: more crowded than 20% of ideas · headwind x0.90

+0.8

government priorities, secondary (1 matching grants)

Trend

Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.

Entrants 2025-26 vs 2023-24 (similar companies)70
Rounds announced 2025+ in the sector68
Sector direction (live batch)100
2026 trend analyst75

Demand

Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.

YC asks for it (current RFS: idea / sector)30
Someone already pays (similar companies, recent / all-time)17
Operator judge: real pain25

100x potential

Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.

Venture judge50
Market size axis33
Moat axis100
Technologist judge100

Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were 000, benchtop, robot, wet-lab, protocol, written, kelvin, bench.

The idea in full

What: Kelvin Bench is a benchtop liquid-handling and imaging robot sold outright to small labs: a two-person biotech, a university group, a contract formulation shop. Protocols are written as text, compiled to machine steps, and every run streams back plate images, timings and outcomes, so the device gets better at execution the more runs the fleet does. Third parties publish protocols and hardware modules against an open SDK and take a share of what they sell, which turns the box from a tool into a platform for research-use-only work that needs no regulatory clearance.
Why now: The current cohort is buying exactly this layer: Omanta (yc S26) pitches "A research lab for one", 10x Science (yc W26) is "the AI-native platform for next-generation protein characterization", AbInitio Bio (yc X26) calls itself "the intelligence layer for drug manufacturing", and Rasyn (yc S26) is chasing "a general intelligence for chemistry" - all of them need physical execution they do not want to build, and the cluster added 126 new companies in 2024 alone, most of them too small to buy an automation suite.
Wedge: first customer and entry point: Sell the first 30 units founder-to-founder into recently funded seed-stage biotechs that have no automation engineer, starting with one protocol family (serial dilution plus plate imaging) that is boring, repetitive and eats a full-time hand.
Path to 100x: Small-lab automation is a $1-10B hardware and consumables market, and the winner is decided by the protocol library, not the chassis: once a few thousand validated protocols only run on Kelvin Bench, buying a competing box means rewriting the lab's methods. Every run is telemetry, so the fleet's success-rate data becomes the reason protocol authors publish here first, and authors bring the next buyers.
Ceiling: Small labs may keep buying human hands instead of capital equipment because a grant pays salaries more easily than instruments, holding unit volume in the low thousands and revenue in the low hundreds of millions.
Closest real companies, as the generator saw them: Omanta is building a research lab for one as a service; Kelvin Bench sells the machine and the protocol marketplace instead of the lab. 10x Science and AbInitio Bio provide software intelligence layers that need a physical executor, which is the position Kelvin Bench occupies. Scala Biodesign designs molecules rather than running the bench work.
Main risk: Hardware reliability in unattended overnight runs falls short, and a $18,000 box that fails one run in ten is returned to the shelf where used liquid handlers already sit.

Five judges

Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).

Venture investor
3/5
Protocol library lock-in is real, but the card concedes unit volume in the low thousands and revenue in low hundreds of millions.
Bootstrapper
2/5
An $18,000 box sold founder-to-founder means inventory, warranty and returns capital far beyond a two-person team's float.
Operator
2/5
The card concedes grants fund salaries more easily than instruments, so an $18,000 capex ask fights the buyer's own budget rules.
Technologist
5/5
A plain-English protocol compiler on owned hardware with run telemetry means the validated protocol library gets harder to leave with every run.
Risk
5/5
Research-use-only means no clearance needed, boxes are sold outright to thousands of independent labs globally, and revenue starts within a year with no gatekeeper in between.
trends
4/5
Rides the robotics cluster jumping from 6% to 13% of the batch, with named S26 buyers like Omanta needing physical execution they will not build.

Similar startups in the directory

Companies whose pitch matches most of the idea's terms (000, benchtop, robot, wet-lab, protocol, written, kelvin, bench): 1 all-time, 1 from the last two years. Same matching as Idea Check.

DeepReach Inc.yc S26 · 2026 · Data for AIalive
Real-world data network for robots & world models

Run this as an Idea Check →

The generator's reference companies

Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.

Public money in this direction

US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.

grants and programs matching the idea

1127

startup-relevant grants in Healthcare and bio

$590M

awarded in the sector, tracked

130

opportunities open now in the sector

Restoring Self-Feeding with a Sensor Driven Robotic Systemawardhigh relevance
NIH / NIA · STTR phase I · $307K · posted 2025-09-20

All public money by sector →

Market signal

What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.

Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch

Healthcare and bio: companies, trend and grants →

Design attributes

The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.

Buyer: Small business
Business model: Hardware
Path to 100x: Platform others build on
Market size: $1-10B market
Capital intensity: Capital-heavy (hardware, bio, infra)
Speed to revenue: Revenue within a year
Technical depth: Real engineering
Go-to-market: Founder-led sales
Moat: Data moat
Geography: Global from day one
Regulation: Unregulated
Vibe: Hot space